The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease.

Cardiac amyloidosis is a rare, infiltrative cardiomyopathy that presents with thickened ventricular walls and progressive heart failure. The morphological findings and clinical features are shared with many other diseases (i.e. hypertrophic cardiomyopathy, 'athlete's heart,' Fabry disease, and hypertensive cardiomyopathy), and misdiagnosis occurs frequently. Cardiologists have many instruments that can help reach a correct diagnosis in a relatively short time. As tiles of a mosaic are placed to create an image, thoughtful and smart use of the different diagnostic tools available allows the opportunity to identify amyloid infiltration of the myocardium. When the myocardium is involved, prognosis is poor, so identification of its involvement is crucial for disease management. The diagnostic process begins with an accurate evaluation of clinical elements and includes cardiovascular imaging (echocardiography, magnetic resonance, and nuclear medicine), electrocardiography, serological assays, and myocardial biopsy; only the appropriate integration of these instruments can reveal the diagnosis to an expert physician. The latest improvements in non-invasive diagnostic techniques with increased diagnostic power have reduced the need for biopsy.

[1]  B. Hazenberg,et al.  Bone scintigraphy with 99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[2]  S. Solomon,et al.  Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis , 2014, Circulation.

[3]  L. Anderson,et al.  CMR-based differentiation of AL and ATTR cardiac amyloidosis. , 2014, JACC. Cardiovascular imaging.

[4]  S. K. White,et al.  Native T1 mapping in transthyretin amyloidosis. , 2014, JACC. Cardiovascular imaging.

[5]  R. Falk,et al.  Left Ventricular Structure and Function in TTR-Related versus AL Cardiac Amyloidosis , 2014 .

[6]  B. Bijnens,et al.  Effect of Combined Systolic and Diastolic Functional Parameter Assessment for Differentiation of Cardiac Amyloidosis From Other Causes of Concentric Left Ventricular Hypertrophy , 2013, Circulation. Cardiovascular imaging.

[7]  A. Sindoni,et al.  Effectiveness of skeletal scintigraphy in transthyretin-related amyloidosis. , 2013, International journal of cardiology.

[8]  M. de Carvalho,et al.  Reduced Myocardial 123-Iodine Metaiodobenzylguanidine Uptake: A Prognostic Marker in Familial Amyloid Polyneuropathy , 2013, Circulation. Cardiovascular imaging.

[9]  M. Robson,et al.  Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. , 2013, JACC. Cardiovascular imaging.

[10]  M. Maurer,et al.  99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses , 2013, Circulation. Cardiovascular imaging.

[11]  A. Mazzeo,et al.  Comparison between (99m)Tc-diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy. , 2013, AJR. American journal of roentgenology.

[12]  Thomas H Marwick,et al.  Normal ranges of left ventricular strain: a meta-analysis. , 2013, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[13]  M. Lubberink,et al.  In Vivo Visualization of Amyloid Deposits in the Heart with 11C-PIB and PET , 2013, The Journal of Nuclear Medicine.

[14]  G. Vita,et al.  Transthyretin‐related familial amyloidotic polyneuropathy: description of a cohort of patients with Leu64 mutation and late onset , 2012, Journal of the peripheral nervous system : JPNS.

[15]  P. Pellikka,et al.  Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study. , 2012, European heart journal cardiovascular Imaging.

[16]  R. Dierckx,et al.  123I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  T. Beck,et al.  Differentiating Cardiac Amyloidosis and Hypertrophic Cardiomyopathy by Use of Three‐Dimensional Speckle Tracking Echocardiography , 2012, Echocardiography.

[18]  L. Padeletti,et al.  Right ventricular function in AL amyloidosis: characteristics and prognostic implication. , 2012, European heart journal cardiovascular Imaging.

[19]  J. Moon,et al.  Updates in Cardiac Amyloidosis: A Review , 2012, Journal of the American Heart Association.

[20]  D. Braconi,et al.  Prevalence of Isolated Atrial Amyloidosis in Young Patients Affected by Congestive Heart Failure , 2012, TheScientificWorldJournal.

[21]  R. Aspinall,et al.  Subacute liver failure secondary to amyloid light-chain amyloidosis. , 2012, Gastroenterology & hepatology.

[22]  P. García-Pavía,et al.  Amiloidosis. Tambien una enfermedad del corazon , 2011 .

[23]  C. Rapezzi,et al.  [Amyloidosis. Also a heart disease]. , 2011, Revista espanola de cardiologia.

[24]  F. Salvi,et al.  Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. , 2011, JACC. Cardiovascular imaging.

[25]  G. Aquaro,et al.  Endocardial and epicardial deformations in cardiac amyloidosis and hypertrophic cardiomyopathy. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[26]  D. Seldin,et al.  Amyloidosis: pathogenesis and new therapeutic options. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Padeletti,et al.  Characteristics of left ventricular rotational mechanics in patients with systemic amyloidosis, systemic hypertension and normal left ventricular mass , 2010, Clinical physiology and functional imaging.

[28]  F. Salvi,et al.  Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  C. Anfuso,et al.  MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy. , 2010, AJR. American journal of roentgenology.

[30]  P. Pellikka,et al.  Abstract 13453: Comparison of Right Ventricular Longitudinal Strain Imaging, Tricuspid Annular Plane Systolic Excursion, and Cardiac Biomarkers for Early Diagnosis of Cardiac Involvement and Risk Stratification in AL Amyloidosis: a Five Year Cohort Study , 2010 .

[31]  A. Foli,et al.  The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis , 2010 .

[32]  M. Benson,et al.  Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis , 2010, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[33]  Alessandro Pingitore,et al.  Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[34]  Matthew W. Martinez,et al.  Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. , 2010, JACC. Cardiovascular imaging.

[35]  F. Salvi,et al.  Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types , 2009, Circulation.

[36]  P. Pellikka,et al.  Doppler myocardial imaging compared to standard two-dimensional and Doppler echocardiography for assessment of diastolic function in patients with systemic amyloidosis. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[37]  James D. Thomas,et al.  Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. , 2009, The American journal of cardiology.

[38]  L. Padeletti,et al.  Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis , 2009, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[39]  D. Pennell,et al.  Cardiovascular Magnetic Resonance and prognosis in cardiac amyloidosis , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[40]  K. Bailey,et al.  Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. , 2008, The American journal of cardiology.

[41]  K. Klingel,et al.  Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. , 2008, Journal of the American College of Cardiology.

[42]  L. Tavazzi,et al.  Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis , 2007 .

[43]  B. Olofsson,et al.  Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[44]  R. Falk,et al.  Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? , 2005, The American journal of cardiology.

[45]  J. Seward,et al.  Differentiation of constrictive pericarditis from restrictive cardiomyopathy using mitral annular velocity by tissue Doppler echocardiography. , 2004, The American journal of cardiology.

[46]  R. Falk,et al.  Longitudinal myocardial velocity gradient derived from pulsed Doppler tissue imaging in AL amyloidosis: a sensitive indicator of systolic and diastolic dysfunction. , 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[47]  R. Falk,et al.  Longitudinal Myocardial Function Assessed by Tissue Velocity, Strain, and Strain Rate Tissue Doppler Echocardiography in Patients With AL (Primary) Cardiac Amyloidosis , 2003, Circulation.

[48]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[49]  T. Miyata,et al.  β2-Microglobulin and Renal Bone Disease , 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[50]  R. Falk,et al.  Right ventricular dilation in primary amyloidosis: an independent predictor of survival. , 1997, The American journal of cardiology.

[51]  R. Kyle,et al.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.

[52]  J. Seward,et al.  Prognostic Significance of Doppler Measures of Diastolic Function in Cardiac Amyloidosis: A Doppler Echocardiography Study , 1991, Circulation.